Sugi Predict

Sugi Predict / Compounds / SCHEMBL3370980

SCHEMBL3370980

SCHEMBL3370980

CS(=O)(=O)OCCC(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 2/20 0.52
▸ TSHR P16473 2/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ MMP9 P14780 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ EPHX2 P34913 3/20 0.33
▸ CDK1 P06493 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ ARNT P27540 1/20 0.31
▸ EPAS1 Q99814 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2077428 0.86 USP2 (0.61) USP2TSHRKDM4EALDH1A1LMNA
SCHEMBL18864591 0.85 USP2 (0.52) USP2TSHRKDM4EALDH1A1LMNA
SCHEMBL9111200 0.83 USP2 (0.50) USP2TSHRKDM4EALDH1A1LMNA
SCHEMBL9826622 0.79 USP2 (0.46) USP2TSHRKDM4EALDH1A1LMNA
SCHEMBL777632 0.79 CA1 (0.44) CA1CA2CA9CDK1CDK2
SCHEMBL4121461 0.78 CA1 (0.34) CA1CA2CA9
SCHEMBL3595211 0.77 USP2 (0.55) USP2TSHRKDM4EALDH1A1LMNA
SCHEMBL778736 0.76 CA1 (0.38) USP2TSHRCA1CA2CA9
SCHEMBL18631984 0.75 CA2 (0.36) TSHRCA1CA2CA9
SCHEMBL780399 0.75 CA2 (0.42) CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240363910-A1 ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE CONTAINING SAME NINGDE AMPEREX TECHNOLOGY LIMITED (CN) 2024-10-31 — — US claimed
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
US-20260055132-A1 TLR7 AGONISTS PRIMMUNE THERAPEUTICS INC (US) 2026-02-26 — — US disclosed
US-12552799-B2 Triazolone compounds NXERA PHARMA UK LIMITED (GB) 2026-02-17 — — US disclosed
US-12528815-B2 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer NXERA PHARMA UK LIMITED (GB) 2026-01-20 — — US disclosed
US-12304907-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-05-20 — — US disclosed
US-12264154-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-04-01 — — US disclosed
US-20250034143-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, LLC (US) 2025-01-30 — — US disclosed
US-12187759-B2 TLR7 agonists Primmune Therapeutics, Inc. (US) 2025-01-07 — — US disclosed
US-20240363910-A1 ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE CONTAINING SAME NINGDE AMPEREX TECHNOLOGY LIMITED (CN) 2024-10-31 — — US disclosed
US-8268823-B2 Medical use of triazine derivatives UNIVERSITY OF GREENWICH (GB) 2012-09-18 — — US disclosed
EP-1863477-B1 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION NOVARTIS AG (CH) 2010-11-03 — — EP disclosed
US-7807709-B2 Organic compounds NOVARTIS AG (CH) 2010-10-05 — — US disclosed
US-20090291954-A1 Medical Use of Triazine Derivatives UNIVERSITY OF GREENWICH (GB) 2009-11-26 — — US disclosed
EP-2043656-A2 NEW MEDICAL USE OF TRIAZINE DERIVATIVES University of Greenwich (GB) 2009-04-08 — — EP disclosed
EP-2012386-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY Mitsubishi Chemical Corporation (JP) 2009-01-07 — — EP disclosed
US-20080194549-A1 Organic Compounds NOVARTIS AG (CH) 2008-08-14 — — US disclosed
WO-2008007149-A2 NEW MEDICAL USE OF TRIAZINE DERIVATIVES UNIVERSITY OF GREENWICH (GB) 2008-01-17 — — WO disclosed
EP-1863477-A1 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION Novartis AG (CH) 2007-12-12 — — EP disclosed
WO-2006100036-A1 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION NOVARTIS AG (CH) 2006-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260055132-A1 TLR7 AGONISTS TLR7, TLR8, TLR1 USP2 2389/4885TSHR 172/4885KDM4E 2863/4885
US-12187759-B2 TLR7 agonists TLR7, TLR1, TLR9 USP2 3419/4885TSHR 503/4885KDM4E 3165/4885
US-20080194549-A1 Organic Compounds REN, ACE, OTC USP2 4135/4885TSHR 2274/4885KDM4E 1370/4885
US-20090291954-A1 Medical Use of Triazine Derivatives KCNH1, KCNJ1, KCNN1 USP2 4758/4885TSHR 1045/4885KDM4E 4441/4885
US-12264154-B2 Compounds and methods of use F12, C1R, ABCG2 USP2 3838/4885TSHR 728/4885KDM4E 3895/4885
US-20250034143-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 USP2 4322/4885TSHR 4540/4885KDM4E 3549/4885
US-12528815-B2 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer ADORA1, ADORA3, OPRL1 USP2 4650/4885TSHR 36/4885KDM4E 4601/4885
US-12304907-B2 Compounds and methods of use F12, C1R, ABCG2 USP2 3838/4885TSHR 728/4885KDM4E 3895/4885
US-12552799-B2 Triazolone compounds ADORA1, ADRA2C, ADORA2A USP2 4097/4885TSHR 43/4885KDM4E 3864/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 USP2 4028/4885TSHR 246/4885KDM4E 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.